Literature DB >> 21769109

Bladder cancer: chemohyperthermia for bladder cancer--clinically effective?

Jeffrey R Gingrich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21769109     DOI： 10.1038/nrurol.2011.104

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  4 in total

Review 1.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

Review 2.  The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.

Authors:  Rianne J M Lammers; J Alfred Witjes; Brant A Inman; Ilan Leibovitch; Menachem Laufer; Ofer Nativ; Renzo Colombo
Journal:  Eur Urol       Date:  2011-04-20       Impact factor: 20.096

Review 3.  Hyperthermia as a treatment for bladder cancer.

Authors:  Edward N Rampersaud; Zeljko Vujaskovic; Brant A Inman
Journal:  Oncology (Williston Park)       Date:  2010-11-15       Impact factor: 2.990

4.  Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).

Authors:  Renzo Colombo; Andrea Salonia; Zvi Leib; Michele Pavone-Macaluso; Dov Engelstein
Journal:  BJU Int       Date:  2010-10-04       Impact factor: 5.588
  4 in total
  6 in total

1.  Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.

Authors:  Keita Uchino; Fumitaka Takeshita; Ryou-U Takahashi; Nobuyoshi Kosaka; Kae Fujiwara; Haruna Naruoka; Satoru Sonoke; Junichi Yano; Hideo Sasaki; Shiari Nozawa; Miki Yoshiike; Kazuki Kitajima; Tatsuya Chikaraishi; Takahiro Ochiya
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

2.  Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.

Authors:  Sicheng Lu; Mengjie Guo; Zhimin Fan; Ying Chen; Xuqin Shi; Chunyan Gu; Ye Yang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

3.  CLT1 targets bladder cancer through integrin α5β1 and CLIC3.

Authors:  Lynn M Knowles; James Zewe; Gunjan Malik; Anil V Parwani; Jeffrey R Gingrich; Jan Pilch
Journal:  Mol Cancer Res       Date:  2012-11-30       Impact factor: 5.852

4.  Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis.

Authors:  Qian Meng; Ting Lei; Min Zhang; Jin Zhao; Xu-Hong Zhao; Man Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-27       Impact factor: 4.553

5.  The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.

Authors:  Chong Li; Song Wu; Haifeng Wang; Xingang Bi; Zhao Yang; Ying Du; Luyun He; Zhiming Cai; Jiansong Wang; Zusen Fan
Journal:  Oncotarget       Date:  2015-08-14

6.  Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells.

Authors:  Shanshan Wang; Qian Meng; Qing Xie; Man Zhang
Journal:  Mol Med Rep       Date:  2017-01-12       Impact factor: 2.952
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.